Ally SX

Primær information

Handelsnavn:
Ally SX Vandopløseligt granulat

Aktiv bestanddel:
metsulfuron-methyl, metsulfuron)

INN (International Name):
metsulfuron-methyl, metsulfuron)

Lægemiddelform:
Vandopløseligt granulat

Sammensætning:
200 g/kg metsulfuron-methyl; (~ 193 g/kg metsulfuron)

Brugt til:
Planter

Medicin typen:
agrokemiske

Dokumenter

for den brede offentlighed:
Oplysningerne indlægssedlen for dette produkt er i øjeblikket ikke tilgængelig, kan du sende en anmodning til vores kundeservice, og vi vil give dig besked, så snart vi er i stand til at opnå det.

Anmode informationsbrochure for offentligheden.

for sundhedspersonale:
Oplysningerne indlægssedlen for dette produkt er i øjeblikket ikke tilgængelig, kan du sende en anmodning til vores kundeservice, og vi vil give dig besked, så snart vi er i stand til at opnå det.

Anmode informationsbrochure for sundhedspersonale.

Lokation

Fås i:
Danmark

Sprog:
dansk

Andre oplysninger

Status

Kilde:
SEGES Landbrug & Fødevarer

Autorisation status:
Markedsført

Autorisationsnummer:
Må ikke anvendes nærmere end 2 meter fra vandmiljøet (vandløb, søer mv.) for at beskytte organismer, der lever i vand (SPe3).

Sidste ændring:
22-07-2018

Oplysningerne indlægssedlen for dette produkt er i øjeblikket ikke tilgængelig, kan du sende en anmodning til vores kundeservice, og vi vil give dig besked, så snart vi er i stand til at opnå det.

Anmode informationsbrochure for offentligheden.

Adgang til dette dokument er kun tilgængelig for registrerede brugere.

Tilmeld dig nu for fuld adgang

25-7-2018

Opinion/decision on a Paediatric investigation plan (PIP): -, Calcium, N,N'-1,2-ethanediylbis[N-[[3-(hydroxy-2-methyl-5-[(phosphonooxy)methyl]-4-pyridinyl]methyl]glycine] manganese complexes, Therapeutic area: Other/Oncology

Europe - EFSA - European Food Safety Authority EFSA Journal

23-7-2018

Orphan designation: synthetic double-stranded siRNA oligonucleotide targeted against transthyretin mRNA, with six phosphorothioate linkages in the backbone, and nine 2'-fluoro and thirty-five 2'-O-methyl nucleoside residues in the sequence, which is cova

Europe - EMA - European Medicines Agency

23-7-2018

Orphan designation: Bardoxolone methyl, for the: Treatment of Alport syndrome

Europe - EMA - European Medicines Agency

13-6-2018

Orphan designation: N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino] benzenesulfonamide dihydrochloride monohydrate, for the: Treatment of post-essential thrombocythaemia myelofibrosis

Europe - EMA - European Medicines Agency

13-6-2018

Orphan designation: N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino] benzenesulfonamide dihydrochloride monohydrate, for the: Treatment of primary myelofibrosis

Europe - EMA - European Medicines Agency

13-6-2018

Orphan designation: N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino] benzenesulfonamide dihydrochloride monohydrate, for the: Treatment of post-polycythaemia vera myelofibrosis

Europe - EMA - European Medicines Agency

29-5-2018

Orphan designation: 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline succinic acid, for the: Treatment of Huntington's disease

Europe - EMA - European Medicines Agency

3-5-2018

Orphan designation: (1'R,6'R)-3-(benzylamine)-6-hydroxy-3'-methyl-4-pentyl-6'-(prop-1-en-2-yl)-[1,1'-bi(cyclohexane)]-2',3,6-triene-2,5-dione, for the: Treatment of systemic sclerosis

Europe - EMA - European Medicines Agency

3-5-2018

Orphan designation: 6'-(R)-methyl-5-O-(5-amino-5,6-dideoxy-α-L-talofuranosyl)-paromamine sulfate, for the: Treatment of mucopolysaccharidosis type I

Europe - EMA - European Medicines Agency

3-5-2018

Orphan designation: 4-[[(1S,4S)-5-[[4-[4-(oxazol-2-yl)phenoxy]phenyl]methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl]benzoic acid, for the: Treatment of cystic fibrosis

Europe - EMA - European Medicines Agency

27-7-2018

EU/3/18/2019 (Reata UK Limited)

EU/3/18/2019 (Active substance: Bardoxolone methyl) - Transfer of orphan designation - Commission Decision (2018)5055 of Fri, 27 Jul 2018 European Medicines Agency (EMA) procedure number: EMA/OD/011/18/T/01